Psoriatic Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2018
MARKET OUTLOOK
Treatment for PsA typically begins with a cDMARD, but often progresses to a tsDMARD or bDMARD within two years. TNFi are the mainstay of treatment for recently treated patients, but newer therapies including two IL-17 inhibitors have a growing market share. Persistency and compliance are highest for Remicade, but Enbrel and Humira continue to capture the largest portion of the bDMARD market.
QUESTIONS ANSWERED
- How long do patients wait between a diagnosis and an initial prescription? How fast do newly diagnosed patients progress through lines of therapy?
- Where in the treatment algorithm will new therapies such as Taltz, Xeljanz, and Orencia fall?
- What changes have taken place in the treatment algorithm within the last three years? What therapies have a growing or shrinking market share?
- How compliant are PsA patients with their prescribed medication? What medications have the highest persistency?
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
